Literature DB >> 16417864

Case of Aicardi-Goutières syndrome with long-lasting increase of cerebrospinal interferon-alpha.

Petia S Dimova1, Olya A Mikova.   

Abstract

Aicardi-Goutières syndrome is a rare progressive encephalopathy characterized by a typical clinical picture, bilateral basal ganglia calcifications, leukodystrophy and brain atrophy, lymphocytosis, and elevated interferon-alpha in the cerebrospinal fluid. Among the cases described to date, variability in the clinical expression or in the cerebrospinal fluid abnormalities has been reported. We present a case with a delayed diagnosis at the age of 8 years, when brain computed tomography was done because there was no first image from the age of 8 months, when the disease started. Symmetric basal ganglia calcifications were visualized and led to purposeful investigation of the cerebrospinal fluid. It revealed an interferon-alpha titer of 103 IU/mL, which, together with the progressive brain damage and disease course, was crucial for the diagnosis. This rare finding of long-term highly elevated interferon-alpha in the cerebrospinal fluid is discussed with respect to the clinical course.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16417864     DOI: 10.1177/08830738050200111101

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  2 in total

1.  Elevation of proinflammatory cytokines in patients with Aicardi-Goutières syndrome.

Authors:  Asako Takanohashi; Morgan Prust; Jichuan Wang; Heather Gordish-Dressman; Miriam Bloom; Gillian I Rice; Johanna L Schmidt; Yanick J Crow; Pierre Lebon; Taco W Kuijpers; Kanneboyina Nagaraju; Adeline Vanderver
Journal:  Neurology       Date:  2013-02-13       Impact factor: 9.910

2.  Relapsing-remitting clinical course expands the phenotype of Aicardi-Goutières syndrome.

Authors:  Jeffrey Lambe; Olwen C Murphy; Weiyi Mu; Krista Sondergaard Schatz; Kristin W Barañano; Arun Venkatesan
Journal:  Ann Clin Transl Neurol       Date:  2020-01-10       Impact factor: 4.511

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.